Ortho Clinical Diagnostics Holdings plc (OCDX) News
Filter OCDX News Items
OCDX News Results
|Loading, please wait...|
OCDX News Highlights
- For OCDX, its 30 day story count is now at 17.
- Over the past 18 days, the trend for OCDX's stories per day has been choppy and unclear. It has oscillated between 1 and 6.
- CIVI, DBI and DOCS are the most mentioned tickers in articles about OCDX.
Latest OCDX News From Around the Web
Below are the latest news stories about Ortho Clinical Diagnostics Holdings plc that investors may wish to consider to help them evaluate OCDX as an investment opportunity.
Ortho Clinical (OCDX) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
OCDX vs. DOCS: Which Stock Is the Better Value Option?
Wall Street Analysts See a 54% Upside in Ortho Clinical (OCDX): Can the Stock Really Move This High?
The consensus price target hints at a 54.3% upside potential for Ortho Clinical (OCDX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
CIVI, DBI, and OCDX made it to the Zacks Rank #1 (Strong Buy) value stocks list on February 18, 2022
In a report released today, Yi Chen from H.C. Wainwright reiterated a Hold rating on Ortho Clinical Diagnostics Holdings (OCDX – Research Report), with a price target of $24.68. The company's shares closed last Wednesday at $16.32, close to its 52-week low of $15.53. According to TipRanks.com, Chen is a 4-star analyst with an average return of 14.7% and a 37.7% success rate. Chen covers the Healthcare sector, focusing on stocks such as HTG Molecular Diagnostics, EyePoint Pharmaceuticals, and Stealth Biotherapeutics. Currently, the analyst consensus on Ortho Clinical Diagnostics Holdings is a Moderate Buy with an average price target of $23.56.
Ortho Clinical Diagnostics Holdings plc (NASDAQ: OCDX ) reported Q4 sales of $521 million , almost in line with the consensus of $521.17 million. The sales increased 0.8% on a reported basis, +1.6% on constant currency, and excluding CoV-2 assays, sales increased 5.0%. Core Revenue increased 3.5% to $518.9 million, up … Full story available on Benzinga.com
SAN DIEGO--(BUSINESS WIRE)--Quidel Corporation (NASDAQ: QDEL), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today financial results for the fourth quarter and year ended December 31, 2021. Fourth Quarter 2021 Highlights Signed definitive agreement to acquire Ortho Clinical Diagnostics Holdings plc ("Ortho"), funded through a combination of cash and newly issued shares in the combined company. Total revenue was $636.
OCDX earnings call for the period ending December 31, 2021.
Ortho Clinical Diagnostics press release (OCDX): Q4 Non-GAAP EPS of $0.18 beats by $0.03.Revenue of $521M (+0.9% Y/Y) misses by $4.26M.
Ortho Clinical Diagnostics Holdings PLC (OCDX) CEO Christopher Smith on Q4 2021 Results - Earnings Call Transcript
No summary available.